Top-Rated Stocks NASDAQ:JAZZ Jazz Pharmaceuticals - JAZZ Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Jazz Pharmaceuticals plc Please log in to your account or sign up in order to add this asset to your watchlist. $154.51 +1.38 (+0.90%) (As of 02/7/2023 12:00 AM ET) Add Compare Share Share Today's Range$150.71▼$154.5650-Day Range$149.93▼$160.4752-Week Range$125.36▼$169.98Volume404,606 shsAverage Volume458,595 shsMarket Capitalization$9.73 billionP/E RatioN/ADividend YieldN/APrice Target$202.55 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Jazz Pharmaceuticals MarketRank™ ForecastAnalyst RatingModerate Buy2.90 Rating ScoreUpside/Downside31.1% Upside$202.55 Price TargetShort InterestHealthy4.18% of Shares Sold ShortDividend StrengthN/ASustainability-1.96Upright™ Environmental ScoreNews Sentiment0.50Based on 11 Articles This WeekInsider TradingSelling Shares$2.97 M Sold Last QuarterProj. Earnings Growth6.13%From $15.18 to $16.11 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.55 out of 5 starsMedical Sector108th out of 1,029 stocksPharmaceutical Preparations Industry43rd out of 504 stocks 3.5 Analyst's Opinion Consensus RatingJazz Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.90, and is based on 9 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $202.55, Jazz Pharmaceuticals has a forecasted upside of 31.1% from its current price of $154.51.Amount of Analyst CoverageJazz Pharmaceuticals has only been the subject of 3 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted4.18% of the outstanding shares of Jazz Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverJazz Pharmaceuticals has a short interest ratio ("days to cover") of 4.8.Change versus previous monthShort interest in Jazz Pharmaceuticals has recently decreased by 2.59%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldJazz Pharmaceuticals does not currently pay a dividend.Dividend GrowthJazz Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreJazz Pharmaceuticals has received a 54.43% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Leukemia medication", "Lung cancer medication", and "Anticoagulant medication (B01)" products. See details.Environmental SustainabilityThe Environmental Impact score for Jazz Pharmaceuticals is -1.96. Previous Next 1.9 News and Social Media Coverage News SentimentJazz Pharmaceuticals has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Jazz Pharmaceuticals this week, compared to 5 articles on an average week.Search InterestOnly 5 people have searched for JAZZ on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Jazz Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -17% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Jazz Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,972,938.00 in company stock.Percentage Held by InsidersOnly 4.40% of the stock of Jazz Pharmaceuticals is held by insiders.Percentage Held by Institutions89.79% of the stock of Jazz Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Jazz Pharmaceuticals are expected to grow by 6.13% in the coming year, from $15.18 to $16.11 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Jazz Pharmaceuticals is -515.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Jazz Pharmaceuticals is -515.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioJazz Pharmaceuticals has a PEG Ratio of 0.90. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioJazz Pharmaceuticals has a P/B Ratio of 2.40. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Jazz Pharmaceuticals (NASDAQ:JAZZ) StockJazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: Xyrem, Xywav, Sunosi, Erwinaze, Vyxeos, Defitelio, and Zepzelca. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.Read More Receive JAZZ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Jazz Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address JAZZ Stock News HeadlinesFebruary 7, 2023 | marketwatch.comAsparaginase Market 2023 to 2029 by Key Players Jazz Pharmaceuticals, Servier Pharmaceuticals, Medac GmbH, Kyowa Hakko KirinFebruary 7, 2023 | marketwatch.comUncovering Hidden Opportunities in the Sleep-Wake Disorder Market (2023-2028)February 7, 2023 | Wall Street Watch Dogs (Ad)A gold storm is coming…“We are in the early stages of a mania – the calm before the storm.”...February 6, 2023 | americanbankingnews.comInsider Selling: Jazz Pharmaceuticals plc (NASDAQ:JAZZ) CEO Sells $155,790.00 in StockFebruary 6, 2023 | americanbankingnews.comJazz Pharmaceuticals plc (NASDAQ:JAZZ) Receives $202.55 Average Target Price from AnalystsFebruary 3, 2023 | marketwatch.comIdiopathic Hypersomnia Treatment Market for the Period 2023 To 2028: With Top Countries Data Analysis and Latest Development PlanFebruary 2, 2023 | benzinga.comCBD-Based Life-Changing Drug For Tuberous Sclerosis Patients, Epidiolex, Now Available Via England's NHSJanuary 31, 2023 | finance.yahoo.comJazz Pharmaceuticals receives NICE recommendation for the reimbursement of Epidyolex® (cannabidiol) for the treatment of seizures associated with tuberous sclerosis complex in EnglandFebruary 7, 2023 | Wall Street Watch Dogs (Ad)A gold storm is coming…“We are in the early stages of a mania – the calm before the storm.”...January 29, 2023 | marketwatch.comMedical Asparaginase Market Dynamics with Top Players, Gross Margin, Regional Demand, Plans and Demand Status Forecast to 2028January 26, 2023 | finance.yahoo.comFDA says it will not regulate CBD and calls on Congress to actJanuary 25, 2023 | finance.yahoo.comStrength Seen in Catalyst (CPRX): Can Its 9.2% Jump Turn into More Strength?January 23, 2023 | marketwatch.comSulfanilamide Market To Show Incredible Growth And Forecast By 2028 Segment, Privacy Tools And Key Players InformationJanuary 23, 2023 | marketwatch.comNonnarcotic Analgesics Market Size 2023 : Segment Overview, Company Profiles, Regional Analysis and Forecast 2029January 23, 2023 | finanznachrichten.deLexaria Bioscience Corp.: Former President of GW Pharmaceuticals USA Joins Lexaria Bioscience as Strategic AdvisorJanuary 19, 2023 | msn.comJazz Pharma, Zymeworks post 84% overall survival for GIT cancer candidateJanuary 19, 2023 | finance.yahoo.comZymeworks shares gain on promising data for cancer drug in development with Jazz PharmaceuticalsJanuary 19, 2023 | finance.yahoo.comJazz Pharma, Zymeworks Highlight 84% Overall Survival At 18 Months From Zanidatamab In Esophageal CancerJanuary 19, 2023 | finance.yahoo.comJazz Pharmaceuticals and Zymeworks Announce 84% Overall Survival at 18 Months from Phase 2 Trial Evaluating Zanidatamab in HER2-Expressing Metastatic Gastroesophageal AdenocarcinomaJanuary 18, 2023 | thestreet.comJazz Pharmaceuticals (JAZZ) Stock Falls in After-Hours Trading on Earnings MissJanuary 16, 2023 | marketwatch.comClozapine Market Size [2023-2028] | Industry Share, Growth Factor, Revenue And Trends Outlook ReportJanuary 14, 2023 | marketwatch.comLewy Body Dementia Treatment Market : Competitive Landscape and Analysis by Recent Trends 2023 to 2028January 13, 2023 | benzinga.comPsychedelic Drugs Market will worth USD 6703.3 million by 2030 : GreyViewsJanuary 12, 2023 | marketwatch.comCytokine Storm Market 2023 : Advance Technology, Latest Trend and Future Expansion by 2028January 11, 2023 | finance.yahoo.com2 Stocks That Beat the Market in 2022 and That Analysts Think Can Go HigherJanuary 6, 2023 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Buy Rating on Novan (NOVN)January 6, 2023 | benzinga.comWill Investors Notice Exciting Sign On Jazz Pharmaceuticals's Chart?See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive JAZZ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Jazz Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address JAZZ Company Calendar Last Earnings11/09/2022Today2/07/2023Next Earnings (Estimated)3/07/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:JAZZ CUSIPG5087110 CIK1232524 Webwww.jazzpharma.com Phone(531) 634-7800Fax353-1634-7850Employees3,200Year Founded2003Price Target and Rating Average Stock Price Forecast$202.55 High Stock Price Forecast$225.00 Low Stock Price Forecast$187.00 Forecasted Upside/Downside+31.1%Consensus RatingModerate Buy Rating Score (0-4)2.90 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($0.30) Trailing P/E RatioN/A Forward P/E Ratio10.18 P/E Growth0.9Net Income$-329,670,000.00 Net Margins-0.52% Pretax Margin-2.17% Return on Equity30.71% Return on Assets9.10% Debt Debt-to-Equity Ratio2.07 Current Ratio3.16 Quick Ratio2.27 Sales & Book Value Annual Sales$3.09 billion Price / Sales3.14 Cash Flow$22.79 per share Price / Cash Flow6.78 Book Value$64.51 per share Price / Book2.40Miscellaneous Outstanding Shares62,970,000Free Float60,195,000Market Cap$9.73 billion OptionableOptionable Beta0.71 Social Links Key ExecutivesBruce C. CozaddChairman & Chief Executive OfficerDaniel N. SwisherPresidentChristopher John ToveyChief Operating Officer & Executive Vice PresidentRenée D. GaláChief Financial Officer & Executive Vice PresidentRobert IannoneChief Medical Officer, EVP-Research & DevelopmentKey CompetitorsPerrigoNYSE:PRGOCorcept TherapeuticsNASDAQ:CORTHorizon Therapeutics PublicNASDAQ:HZNPCatalentNYSE:CTLTSarepta TherapeuticsNASDAQ:SRPTView All CompetitorsInsiders & InstitutionsBraun Stacey Associates Inc.Bought 242 shares on 2/7/2023Ownership: 0.188%Aviance Capital Partners LLCSold 447 shares on 2/7/2023Ownership: 0.016%LPL Financial LLCBought 1,198 shares on 2/7/2023Ownership: 0.016%Commonwealth Equity Services LLCSold 96 shares on 2/7/2023Ownership: 0.015%IFP Advisors IncBought 75 shares on 2/7/2023Ownership: 0.001%View All Insider TransactionsView All Institutional Transactions JAZZ Stock - Frequently Asked Questions Should I buy or sell Jazz Pharmaceuticals stock right now? 10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Jazz Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" JAZZ shares. View JAZZ analyst ratings or view top-rated stocks. What is Jazz Pharmaceuticals' stock price forecast for 2023? 10 Wall Street research analysts have issued 12-month target prices for Jazz Pharmaceuticals' shares. Their JAZZ share price forecasts range from $187.00 to $225.00. On average, they anticipate the company's stock price to reach $202.55 in the next twelve months. This suggests a possible upside of 33.2% from the stock's current price. View analysts price targets for JAZZ or view top-rated stocks among Wall Street analysts. How have JAZZ shares performed in 2023? Jazz Pharmaceuticals' stock was trading at $159.31 at the beginning of 2023. Since then, JAZZ shares have decreased by 4.5% and is now trading at $152.10. View the best growth stocks for 2023 here. When is Jazz Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023. View our JAZZ earnings forecast. How were Jazz Pharmaceuticals' earnings last quarter? Jazz Pharmaceuticals plc (NASDAQ:JAZZ) announced its earnings results on Wednesday, November, 9th. The specialty pharmaceutical company reported $4.53 earnings per share for the quarter, topping analysts' consensus estimates of $4.35 by $0.18. The specialty pharmaceutical company earned $940.65 million during the quarter, compared to the consensus estimate of $939.88 million. Jazz Pharmaceuticals had a positive trailing twelve-month return on equity of 30.71% and a negative net margin of 0.52%. What guidance has Jazz Pharmaceuticals issued on next quarter's earnings? Jazz Pharmaceuticals updated its FY 2022 earnings guidance on Friday, December, 9th. The company provided earnings per share (EPS) guidance of $17.20-$17.85 for the period, compared to the consensus earnings per share estimate of $17.41. The company issued revenue guidance of $3.60 billion-$3.70 billion, compared to the consensus revenue estimate of $3.65 billion. What is Bruce C. Cozadd's approval rating as Jazz Pharmaceuticals' CEO? 60 employees have rated Jazz Pharmaceuticals Chief Executive Officer Bruce C. Cozadd on Glassdoor.com. Bruce C. Cozadd has an approval rating of 92% among the company's employees. This puts Bruce C. Cozadd in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Jazz Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Jazz Pharmaceuticals investors own include Ligand Pharmaceuticals (LGND), Gilead Sciences (GILD), Alibaba Group (BABA), Micron Technology (MU), NVIDIA (NVDA), Netflix (NFLX), Tesla (TSLA), AbbVie (ABBV), Bank of America (BAC) and Biogen (biib). What is Jazz Pharmaceuticals' stock symbol? Jazz Pharmaceuticals trades on the NASDAQ under the ticker symbol "JAZZ." Who are Jazz Pharmaceuticals' major shareholders? Jazz Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Pacer Advisors Inc. (0.54%), Wedge Capital Management L L P NC (0.40%), Retirement Systems of Alabama (0.28%), Sumitomo Mitsui Trust Holdings Inc. (0.28%), Todd Asset Management LLC (0.28%) and Allspring Global Investments Holdings LLC (0.20%). Insiders that own company stock include Anne Oriordan, Bruce C Cozadd, Bruce C Cozadd, Christopher J Tovey, Elmar Schnee, Finbar Larkin, James E Flynn, Jennifer E Cook, Kim Sablich, Mark Douglas Smith, Michael Patrick Miller, Neena M Patil, Patricia Carr, Patrick G Enright, Paul L Berns, Peter Gray, Renee D Gala, Robert Iannone, Samantha Pearce and Seamus Mulligan. View institutional ownership trends. How do I buy shares of Jazz Pharmaceuticals? Shares of JAZZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Jazz Pharmaceuticals' stock price today? One share of JAZZ stock can currently be purchased for approximately $152.10. How much money does Jazz Pharmaceuticals make? Jazz Pharmaceuticals (NASDAQ:JAZZ) has a market capitalization of $9.58 billion and generates $3.09 billion in revenue each year. The specialty pharmaceutical company earns $-329,670,000.00 in net income (profit) each year or ($0.30) on an earnings per share basis. How many employees does Jazz Pharmaceuticals have? The company employs 3,200 workers across the globe. Does Jazz Pharmaceuticals have any subsidiaries? The following companies are subsidiares of Jazz Pharmaceuticals: Cavion.Read More How can I contact Jazz Pharmaceuticals? Jazz Pharmaceuticals' mailing address is FIFTH FLOOR WATERLOO EXCHANGE WATERLOO ROAD, DUBLIN L2, D04. The official website for the company is www.jazzpharma.com. The specialty pharmaceutical company can be reached via phone at (531) 634-7800, via email at investorinfo@jazzpharma.com, or via fax at 353-1634-7850. This page (NASDAQ:JAZZ) was last updated on 2/7/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.